Novo Nordisk
Novo Nordisk Continues Impressive Growth in Weight-Loss and Diabetes Drugs Market
Novo Nordisk, the maker of Wegovy and Ozempic, projects double-digit growth with soaring demand and supply boosts.
See moreNovo Nordisk, the maker of Wegovy and Ozempic, projects double-digit growth with soaring demand and supply boosts.
See moreNovo Nordisk's oral weight-loss drug, Amycretin, is causing waves with a 13.1% weight loss in early trials! 🚀 #NovoNordisk #Amycretin #WeightLoss
See moreUgentlig opdatering af BOUT ETF tracker aktieselskaber på IBD Breakout Stocks Index, inklusiv Alphabet!
See moreFind out how Novo Nordisk is dominating the weight-loss market with its blockbuster drugs! #NovoNordisk #WeightLoss
See moreNovo Nordisk er optimistisk om, at Kalundborg-branden ikke vil forsinke virksomhedens ekspansion. Læs mere her!
See moreSkandalen fortsætter med Novo Nordisk, der oplever brand i deres kontorbygning i Danmark for anden gang på en uge! Læs mere her.
See moreNovo Nordisk kæmper med Wegovy-salg og hjerteproblemer, men der er lys i mørket!
See more